drugset / Trial / NCT04364997
Study of Desvenlafaxine in Treating Major Depressive Disorder.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary purpose of this study is to evaluate if the effectiveness of desvenlafaxine succinate sustained-release tablet (50 mg/day) used for 8 weeks is not inferior to duloxetine hydrochloride enteric-coated capsule (60 mg/day) in adult patients with major depressive disorder.
Timeline
- Start
- 2020-06-18
- Primary completion
- 2021-09-22
- Completion
- 2021-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desvenlafaxine | Other / unclassified | 50 mg | Oral |
| Subject | Duloxetine | Small molecule | 60 mg | Oral |